Head to head
Petrelintide against Semaglutide
An amylin analogue against a GLP-1 agonist, which is a comparison between two different appetite pathways rather than two versions of the same one. The tolerability argument for amylin analogues is the reason people look at this pair, and it has not been settled in a head to head trial.
Column A
PetrelintidePetrelintide (long-acting amylin analogue)
A once-weekly amylin analogue from Zealand and Roche being developed as a potentially better-tolerated obesity treatment, with positive Phase 2 results.
Column B
SemaglutideSemaglutide (GLP-1 receptor agonist)
A long-acting GLP-1 receptor agonist approved for type 2 diabetes and chronic weight management, with proven cardiovascular risk reduction.
Side by side, on the facts we can check
| Attribute | Petrelintide | Semaglutide |
|---|---|---|
| Category | Metabolic | Metabolic |
| FDA status | Investigational (Phase 3 planned to start in the second half of 2026) | FDA-approved (Ozempic, Rybelsus for T2D; Wegovy injection, Wegovy pill approved Dec 2025, and Wegovy HD 7.2 mg approved Mar 2026 for weight management) |
| Half-life | Supports weekly dosing | ~7 days |
| Molecular weight | 4,192 Da | 4,113.6 Da |
| Mechanism | Agonizes amylin receptors to promote satiety and slow gastric emptying, used as a single-agent weight-loss approach. | Activates the GLP-1 receptor, increasing insulin secretion when glucose is elevated, suppressing glucagon, slowing gastric emptying, and acting on hypothalamic appetite centers to reduce food intake. |
| Human studies cited | 2 | 5 |
| Legal status, US | Investigational, not approved | FDA-approved, prescription only |
Frequently asked questions
What is the difference between Petrelintide and Semaglutide?
Petrelintide: A once-weekly amylin analogue from Zealand and Roche being developed as a potentially better-tolerated obesity treatment, with positive Phase 2 results. Semaglutide: A long-acting GLP-1 receptor agonist approved for type 2 diabetes and chronic weight management, with proven cardiovascular risk reduction.
Which has stronger research evidence, Petrelintide or Semaglutide?
This database does not grade compounds. It counts what was run in people: 2 of the 3 studies cited on the Petrelintide profile were human work, against 5 of 5 for Semaglutide. Those counts are of our own citation lists and understate any larger literature, and neither is a recommendation.
Are Petrelintide and Semaglutide FDA-approved?
Petrelintide: Investigational (Phase 3 planned to start in the second half of 2026). Semaglutide: FDA-approved (Ozempic, Rybelsus for T2D; Wegovy injection, Wegovy pill approved Dec 2025, and Wegovy HD 7.2 mg approved Mar 2026 for weight management).
Related posts
Blog articles that cover Petrelintide or Semaglutide, newest first.
- Dispatch / Sep 12, 2026 / 8 minDispatch 001: Five Retatrutide Phase 3 Trials Have Finished And None Has Posted Results
- Metabolic / Sep 8, 2026 / 8 minTesofensine Is Not a Peptide: What It Is, the Trials, and the Heart-Rate Issue
- Longevity / Sep 8, 2026 / 12 minPeptides for Longevity: What the Evidence Actually Shows in 2026
- Metabolic / Sep 8, 2026 / 10 minOral GLP-1s in 2026: Wegovy Pill vs Foundayo (Orforglipron) vs Rybelsus, and What Is Coming
Reviewed Sep 2026. This page sets two published records side by side. It is educational, it is not medical advice, and it contains no dosing protocols or recommendations for personal use.